SDI Offers Free Webinars to Help Life Scientists Get Better Antibodies in Less Time

Attendees Learn How Genomic Antibody Technology™ Generates Antibodies Directly From Protein Sequence

• Press Release
• Source: Strategic Diagnostics Inc. (SDI)
• On 10:35 am EDT, Wednesday September 30, 2009

NEWARK, Del.--(BUSINESS WIRE)--SDI (Strategic Diagnostics Inc., NASDAQ: SDIX) will host three free online lectures during October and November this year to help scientists enhance their research process flow using a new technology. For over 20 years, SDI has created antibodies that advance immuno-based work helping scientists and other customers reduce time, labor, and costs while increasing accuracy and reliability of test results.

Related Quotes

Symbol	Price	Change
SDIX	1.26	0.00

{"s" : "sdix","k" : "c10,l10,p20,t10","o" : "","j" : ""}

WHAT:

SDI will host three free online lectures to help research scientists learn how antibodies can be generated directly from a protein sequence using Genomic Antibody Technology (GAT).

WHO:

The webinars are intended for researchers from pharmaceutical, academic, diagnostic, government and other life science organizations. The online lectures will be presented by Dr. Ross Chambers, Senior Scientist at SDI. Dr. Chambers is an expert on the development of antibodies based on DNA immunization technologies. Prior to joining SDI, Dr. Chambers was an Assistant Professor at the University of Texas Southwestern Medical Center.

WHERE:

Online, at your computer location. To register, go to www.sdix.com/attend or call us at 800-544-8881.

WHEN:

• Tuesday, October 6 at 11am Eastern
• Thursday, October 22 at 1pm Eastern
• Monday, November 9 at 3pm Eastern

WHY: Seminar attendees will learn how they can benefit from of GAT, including:

• Up to 50% reduction in antibody development costs
• Increased assay success rates
• Elimination of the need to create protein antigen
• Native conformation of antigen expressed in vivo for structural fidelity
• Using a sequenced-based development that complements other discovery platforms

About Strategic Diagnostics Inc. (SDI)

Strategic Diagnostics Inc. develops, manufactures, and markets biotechnology-based products and services across industrial, academic, pharmaceutical, diagnostic, human health and Life Science markets – from food safety test kits to diagnostic-grade antibody solutions.

For over 20 years, SDI has created antibodies that advance our customers’ and partners’ immuno-based work for assay development and industrial testing, helping them reduce time, labor, and costs while increasing accuracy and reliability of test results. Unique SDI capabilities include Genomic Antibody Technology™ (GAT) for rapid development of diagnostic-grade clinical assays and research projects– from antibody candidate to critical high-quality reagent formulation.

SDI continues to leverage its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to broaden its position into the diagnostics, life science and pharmaceutical research markets. For more information, visit www.sdix.com.

This release may contain forward-looking statements reflecting SDI's current expectations. When used in this press release, words like “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.

SDI Company Contact:
Glenn Frantz
Director, Communications
(302) 456-6789
gfrantz@sdix.com
or
SDI Investor Contact:
The Trout Group
Brian Korb
(646) 378-2923
bkorb@troutgroup.com